Management of Oral Lesions after COVID-19 Vaccination

covid vaccine vial

I recently had a patient who had salivary gland problems after vaccination and when I looked in her mouth I saw unusual lesions at the orifice of the parotid duct. I wondered if there were any solutions.

Joseph et al published a brief summary of the litany of oral/facial problems that develop after COVID-19 vaccination.

“Most common oral lesions reported in the literature following COVID-19 vaccination include maculae, petechiae, desquamation, edema, erythema multiforme-like lesions, erosions, and ulcers on the hard palate, oral floor, lips, tongue, and gingiva (Chun et al., 2022; Mazur et al., 2021; Sayare et al., 2021). Few studies also reported pemphigus vulgaris, bullous pemphigoid, herpes zoster, lichen planus, Stevens–Johnson syndrome, Behçet’s disease, Bell’s palsy, facial swelling, and lips, face, or tongue swelling associated with anaphylaxis, burning mouth syndrome, and oral candidiasis (Chun et al., 2022; Mazur et al., 2021; Thongprasom et al., 2021).”

Then the authors go on to give some very practical solutions I plan to keep in mind for my clinic.

Joseph B, Yadalam PK, Anegundi RV. Management of oral lesions following COVID-19 vaccination. Oral Dis. 2022 Nov;28 Suppl 2:2634-2635. doi: 10.1111/odi.14342. Epub 2022 Aug 16. PMID: 35933735; PMCID: PMC9538565.

“In most cases, after consulting a physician to rule out any other medical issue, application of 0.1% dexamethasone solution thrice daily, 50 mg/g nystatin syrup five times daily, acyclovir ointment, and 0.1% chlorhexidine gargle twice daily relieved the symptoms. Similarly, lichen planus in the buccal mucosa resolved with 0.1% dexamethasone solution, nystatin solution (100,000 U/mL), and 0.1% dexamethasone gargle thrice daily. Neuropathic pain following the COVID-19 vaccination was managed by 0.5 mg clonazepam and 150 mg pregabalin daily. Burning-mouth syndrome was relieved using a 2% lidocaine gargle daily and 10 mg nortriptyline. Oral candidiasis cases found relief using 0.5 mg clonazepam and fluconazole syrup regularly. All cases were resolved within a varying period of 1 week to 1 month, while some even took up to 2 months. These treatments significantly relieved all symptoms, including tongue pain and ulcerative lesions. However, erythema of palatal gingiva took a few weeks longer (Chun et al., 2022). It is recommended that after COVID-19 vaccination, patients may avoid high-intensity workouts, alcohol consumption, and smoking for a few days after vaccination.”

Source: Substack

Please Donate Below To Support Our Ongoing Work To Defend The Scientific Method

PRINCIPIA SCIENTIFIC INTERNATIONAL, legally registered in the UK as a company incorporated for charitable purposes. Head Office: 27 Old Gloucester Street, London WC1N 3AX. 

Trackback from your site.

Comments (1)

  • Avatar

    Wisenox

    |

    “Few studies also reported pemphigus vulgaris, bullous pemphigoid”

    As usual, the patents have explanations, but insider-Mccullough doesn’t mention it.
    Many of these conditions can arise from elevated IG4 antibodies, which are pathogenic in large numbers.
    So, where would they be coming from? Immune evasion and avoidance. They have to shut down or cripple the immune system in order to get their lipid nanoparticles past the liver and spleen. For example, to make it to the testes or ovaries, the liver macrophages must be hindered.
    They have technology, chimeric antibodies, that are used to shut down macrophages. If you cross-link receptors on a macrophage, it assumes the pathogen is too big and leaves it alone; similar to the way that HIV glycoprotein 127 works.
    To crosslink, they use antibodies, which have a ‘Y’ shape. The front 2 are from a macaque monkey and bind many times stronger than the human counterparts. So, when they latch onto a macrophage, they aren’t letting go.
    The problem is that the heavy back end of the antibody can still bind with other macrophages, and if this occurs, immune responses will occur anyway.
    The solution is to use IG4 antibodies instead of the more common IGG. The back end of IG4 antibodies have very low binding affinity, and will often detach very quickly. This is great for shutting down immunity, but then incurs the risk of IG4 toxicity.
    There are other explanations in the patents as well, but the insiders don’t talk about them.

    Remember, if you took a swab test or vaccine, be sure to get an answer from your representatives regarding intellectual property rights claims over humans. There’s a reason they won’t talk about it.

    Reply

Leave a comment

Save my name, email, and website in this browser for the next time I comment.
Share via